Corline Biomedical AB

As of June 30, 2026, Corline Biomedical AB carries a market capitalization of 469.09M, placing it among publicly traded companies globally. Its enterprise value stands at 436.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Corline Biomedical AB's next confirmed earnings release is scheduled for November 19, 2026.

As of June 30, 2026, Corline Biomedical AB has 26.13M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 36.85, and the price-to-book ratio stands at 4.74.

These figures are as of June 30, 2026. The EV/Sales ratio of 35.21 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 436.10M versus a market cap of 469.09M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Corline Biomedical AB maintains a current ratio of 6.48, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Corline Biomedical AB posted a negative return on equity (ROE) of -13.72, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.29, reflecting losses generated across the asset base.

As of the close on October 23, 2026, Corline Biomedical AB's stock has declined approximately 31.12% over the past 52 weeks. The 50-day moving average sits at 15.28, while the 200-day moving average is 16.56.

Over the twelve months ended June 30, 2026, Corline Biomedical AB generated 12.39M in revenue and converted that into -12.32M in net income, yielding earnings per share of -0.48. EBITDA reached -12.27M, while operating income came in at -12.36M.

These figures are as of June 30, 2026. Total book value stands at 99.00M, with working capital of 33.20M providing operational flexibility.

Corline Biomedical AB produced -14.46M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -732,000.00 in capital expenditures, free cash flow totaled -15.19M - equivalent to -0.60 per share.

Over the twelve months ended June 30, 2026, Corline Biomedical AB posted a gross margin of 91.65, reflecting its pricing power and cost economics. The operating margin of -99.76 and net profit margin of -99.48 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.50, meaning Corline Biomedical AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Corline Biomedical AB's most recent stock split took place on January 4, 2021 with a 141:145 split ratio.

As of June 30, 2026, Corline Biomedical AB has an Altman Z-Score of 12.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.